KEY TAKEAWAYS
- The study aimed to investigate the influence of VCAN, CD3G, and C1QB on tumor purity, prognosis, and drug sensitivity in patients with DLBCL.
- Researchers noticed that VCAN, CD3G, and C1QB significantly influenced tumor purity, drug sensitivity, and prognosis.
Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant B-cell lymphoma. Although various treatments have been developed, the limited efficacy calls for more and further exploration of its characteristics.
Zhenbang Ye and the team aimed to investigate the influence of VCAN, CD3G, and C1QB on tumor purity, prognosis, and drug sensitivity in patients with DLBCL.
Researchers performed an inclusive analysis using datasets from the Gene Expression Omnibus (GEO) database to identify the tumor purity of DLBCL. Survival analysis was employed to analyze the prognosis of patients with DLBCL.
Immunohistochemistry was conducted to detect important factors influencing prognosis. Additionally, drug-sensitive prediction was performed to evaluate the value of the model in determining drug response in patients with DLBCL.
Researchers identified VCAN, CD3G, and C1QB as 3 key genes that impacted the outcome of DLBCL patients both in GEO datasets and samples from their centers. Among them, VCAN and CD3G+ T cells were correlated with a favorable prognosis, while C1QB was correlated with a worse prognosis. The ratio of CD68+ macrophages and CD8+ T cells was associated with a better prognosis.
Additionally, the CD3G+ T cells ratio was significantly correlated with CD68+ macrophages, CD4+ T cells, and CD8+ T cells ratios, indicating it could play an important role in anti-tumor immunity in DLBCL. The riskScore model constructed based on the RNASeq data of VCAN, C1QB, and CD3G worked well in predicting prognosis and drug sensitivity.
The study concluded that VCAN, CD3G, and C1QB were 3 key genes that influenced the tumor purity of DLBCL and could also exert a significant impact on drug sensitivity and prognosis of patients with DLBCL.
This study is funded by the Shenzhen High-level Hospital Construction Fund and CAMS Innovation Fund for Medical Sciences.
Source: https://pubmed.ncbi.nlm.nih.gov/38980810/
Ye Z, Huang N, Fu Y, et al. (2024). “Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients.” Elife. 2024 Jul 9;13:RP92841. doi: 10.7554/eLife.92841. PMID: 38980810; PMCID: PMC11233133.
